Desloratadine in the treatment of allergic perennial rhinitis. A multicenter study in Poland;Desloratadyna w leczeniu całorocznego alergicznego nieżytu nosa - Wieloośrodkowe badania w Polsce

Alergia Astma Immunologia

Volumn 8, Issue 2, 2002, Pages 101-105

  Ciebiada, Maciej ^a   Górska Ciebiada, Małgorzata ^a   Górski, Paweł ^a  

^a Medical University of Lodz Klinika Pneumonologii i Alergologii   (Poland)

Author keywords

Desloratadine; Efficacy; Perennial allergic rhinitis; Side effects

Indexed keywords

ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; DESLORATADINE; HISTAMINE H1 RECEPTOR ANTAGONIST;

ALLERGIC RHINITIS; ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; POLAND; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0036354079     PISSN: 14273101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Desloratadine
2. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis
3. Doubleblind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 once daily) and cetirizine in seasonal allergic rhinitis
4. Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: A randomized, double-blind, placebo-controlled study
5. Functinal characterization of desloratadine and other antihistamines in human H1 receptors
6. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist
7. In vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3)
8. Loratadine and desethoxycarbonylloratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells
9. Inhibition of cytokine secretion from human leukemic mast cells and basophils by h1 and H2 receptor antagonists
10. Inhibition of cytokine generation and mediator release in human basophils by desloratadine
11. Loratadine reduces RANTES release by an epithelial cell line
12. Desloratadine attenuation of eosinophil chemotaxis, adhesion, and superoxide generation
13. Desloratadine and ketokonazole: Pharmakokinetics and electrocardiographic pharmacodynamic effect
14. Efffect of desloratadine on P-glycoprotein (P-gp) transport system (MDRI)
15. Effect of descarboxyethoxyloratadine, the major metabolite of loratadine, on human cardiac potassium channel Kv1.5
16. Efficacy and tolerabitlity of once-daily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis
17. Quality of life in patients with seasonal allergic rhinitis is improved by desloratadine
18. Health-related qualty of life outcomes of desloratadine in patints with moderate-severe SAR
19. Desloratadine reduces the use of inhaled beta2-agonists and improves asthma symptoms in patients with seasonal allergic rhinitis and asthma
20. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study